Objective: This study presents real-life experience with cefiderocol used on a compassionate basis for treatment of three patients with severe infections caused by extensively/pan-drug resistant (XDR/PDR) Acinetobacter baumannii (Ab).
Methods: Serum bactericidal activity was determined and considered as a surrogate of cefiderocol susceptibility.
Results: Clinical improvement and microbiological eradication of A. baumannii were observed in all three patients, who were affected by extremely complex conditions either for type of infection, adverse effect or resistance profile of A. baumannii.
Conclusion: Cefiderocol for XDR/PDR-Ab infections might be reconsidered, especially in light of the recent disappointing results of the CREDIBLE-CR study.
Keywords: Cefiderocol; Extensively and pan-resistant acinetobacter baumannii; Serum bactericidal activity; Spondylodiscitis.
Copyright © 2020. Published by Elsevier Ltd.